FrancophonIA/ELRC3.0 huggingface dataset:
English: 4b recommendation: Regardless of the dog's body weight, using the applicator tip, part the hair at the base of the tail and begin applying the veterinary medicine directly onto the skin in a continuous line from the base of the tail along the centre of the back all the way up to the shoulder blades, as shown in the diagram, squeezing the applicator until it is empty.
Estonian: Lükake karvad laiali, kuni paljastub koera nahk, ja kandke veterinaarravim alates saba lähtekohast kuni abaluudeni mööda selja keskosa pideva joonena otse nahale, nagu on näidatud alloleval joonisel.
English: Apart from local skin redness and cosmetic hair coat changes where the veterinary medicine was applied, no adverse reactions were observed in healthy puppies aged 7 weeks, given the veterinary medicine on the skin 7 times at 2-week intervals and with up to 5 times the highest recommended dose.
Estonian: Tervetel 7 nädala vanustel kutsikatel, keda raviti 2-nädalaste intervallide tagant maksimaalsest annusest kuni 5 korda suuremate annustega, ei täheldatud muid kõrvaltoimeid peale nahapunetuse ja karvkatte kosmeetiliste muutuste manustamiskohas.
English: It also kills mosquitoes (Aedes aegypti) and stable flies for one month after use.
Estonian: Samuti hävitab see ühe kuu vältel pärast kasutamist sääsed (Aedes aegypti) ja pistekärbsed.
English: Apart from erythema and cosmetic hair coat changes at the site of application, no adverse reactions were observed in healthy puppies aged 7 weeks, topically treated 7 times at 2 week intervals and with up to 5 times the highest recommended dose.
Estonian: Üleannustamine (sümptomid, esmaabi, antidoodid) Tervetel 7 nädala vanustel kutsikatel, keda raviti 2-nädalaste intervallide tagant maksimaalsest annusest kuni 5 korda suuremate annustega, ei täheldatud muid kõrvaltoimeid peale nahapunetuse ja karvkatte kosmeetiliste muutuste manustamiskohas.
English: Pale yellow solution.
Estonian: Helekollane lahus.
English: for dogs 1.5-4 kg
Estonian: Koerad kehakaaluga alates 1,5 kg kuni 4 kg
English: Dogs over 10 kg and up to 40 kg body weight
Estonian: Koerad kehakaaluga üle 10 kg kuni 40 kg
English: Dogs over 4 kg and up to 10 kg body weight
Estonian: Koerad kehakaaluga üle 4 kg kuni 10 kg
English: Dogs over 40 kg body weight
Estonian: Koerad kehakaaluga üle 40 kg
English: It prevents biting from sand flies (Phlebotomus perniciosus), mosquitoes (Culex pipiens, Aedes aegypti) and from stable flies (Stomoxys calcitrans) for one month post-application.
Estonian: Veterinaarravim hoiab ühe kuu vältel pärast pealekandmist ära kihulaste (Phlebotomus perniciosus), sääskede (Culex pipiens, Aedes aegypti) ja pistekärbeste (Stomoxys calcitrans) nõelamised.
English: Vectra 3D for dogs > 25-40 kg for dogs > 40 kg
Estonian: Vectra 3D > 25-40 kg koertele
English: Weight of dog (kg)
Estonian: Koera kehakaal (kg)
English: The treatment prevents flea infestation for one month.
Estonian: Ravi hoiab ühe kuu vältel ära uue kirbunakkuse.
English: Sand flies, mosquitoes and stable flies:
Estonian: Kihulased, sääsed ja pistekärbsed
English: Vectra 3D for dogs 1.5-4 kg for dogs > 4-10 kg
Estonian: Vectra 3D 1,5-4 kg koertele
English: See package leaflet for instructions for use.
Estonian: Vaadake kasutusjuhendit pakendi infolehest.
English: Permethrin is acaricide and insecticide.
Estonian: Permetriin on akaritsiid ja insektitsiid.
English: Each spot-on applicator contains dinotefuran 44 mg / pyriproxyfen 3.9 mg / permethrin 317 mg Each spot-on applicator contains dinotefuran 87 mg / pyriproxyfen 7.7 mg / permethrin 635 mg Each spot-on applicator contains dinotefuran 196 mg / pyriproxyfen 17.4 mg / permethrin 1429 mg Each spot-on applicator contains dinotefuran 256 mg / pyriproxyfen 22.7 mg / permethrin 1865 mg Each spot-on applicator contains dinotefuran 436 mg / pyriproxyfen 38.7 mg / permethrin 3175 mg
Estonian: Üks täpiravimi aplikaator sisaldab 436 mg dinotefuraani / 38,7 mg püriproksüfeeni / 3175 mg permetriini.
English: The attachment of a single tick after treatment cannot be excluded.
Estonian: Ei saa välistada, et pärast antud veterinaarravimi kasutamist kinnitub nahale mõni üksik puuk.
English: Vectra 3D for dogs > 4-10 kg for dogs > 10-25 kg
Estonian: Vectra 3D > 4-10 kg koertele
English: Vectra 3D for dogs > 10-25 kg for dogs > 25-40 kg Purple
Estonian: Vectra 3D > 10-25 kg koertele
English: 4.9 Amounts to be administered and administration route Dosage:
Estonian: 4.9 Annustamine ja manustamisviis
English: PACKAGE LEAFLET: Vectra 3D spot-on solution for dogs 1.5-4 kg Vectra 3D spot-on solution for dogs > 4-10 kg Vectra 3D spot-on solution for dogs > 10-25 kg Vectra 3D spot-on solution for dogs > 25-40 kg Vectra 3D spot-on solution for dogs > 40 kg
Estonian: PAKENDI INFOLEHT Vectra 3D täpilahus 1,5-4 kg koertele Vectra 3D täpilahus > 4-10 kg koertele Vectra 3D täpilahus > 10-25 kg koertele Vectra 3D täpilahus > 25-40 kg koertele Vectra 3D täpilahus > 40 kg koertele
English: Vectra 3D spot-on solution for dogs 1.5-4 kg Vectra 3D spot-on solution for dogs > 4-10 kg Vectra 3D spot-on solution for dogs > 10-25 kg Vectra 3D spot-on solution for dogs > 25-40 kg Vectra 3D spot-on solution for dogs > 40 kg dinotefuran / pyriproxyfen / permethrin
Estonian: Vectra 3D täpilahus 1,5-4 kg koertele Vectra 3D täpilahus > 4-10 kg koertele Vectra 3D täpilahus > 10-25 kg koertele Vectra 3D täpilahus > 25-40 kg koertele Vectra 3D täpilahus > 40 kg koertele dinotefuraan/püriproksüfeen/permetriin
English: This will pierce the seal.
Estonian: See läbistab kaitseplommi.
English: METHOD AND ROUTE(S) OF ADMINISTRATION Spot-on use for external application to the skin.
Estonian: MANUSTAMISVIIS JA -TEE(D) Täppmanustamine.
English: Vectra 3D spot-on solution for dogs 1.5-4 kg Vectra 3D spot-on solution for dogs > 4-10 kg Vectra 3D spot-on solution for dogs > 10-25 kg Vectra 3D spot-on solution for dogs > 25-40 kg Vectra 3D spot-on solution for dogs > 40 kg
Estonian: Vectra 3D täpilahus 1,5-4 kg koertele Vectra 3D täpilahus >4-10 kg koertele Vectra 3D täpilahus > 10-25 kg koertele Vectra 3D täpilahus > 25-40 kg koertele Vectra 3D täpilahus > 40 kg koertele
English: Treatment schedule:
Estonian: Ravimi pealekandmine
English: DOSAGE FOR EACH SPECIES, ROUTE AND METHOD OF ADMINISTRATION Spot-on use.
Estonian: ANNUSTAMINE LOOMALIIGITI, MANUSTAMISVIIS(D) JA -MEETOD
English: Ozempic semaglutide
Estonian: Ozempic semaglutiid
English: What measures are being taken to ensure the safe and effective use of Ozempic?
Estonian: Mis meetmed võetakse, et tagada Ozempici ohutu ja efektiivne kasutamine?
English: The full EPAR for Ozempic can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Ozempici kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: These are mild or moderate in severity and of short duration.
Estonian: Need on raskusastmelt tavaliselt kerged või mõõdukad ja lühiajalised.
English: If needed, the dose can be further increased up to a maximum of 1 mg once a week.
Estonian: Vajaduse korral võib annust suurendada maksimaalselt 1 milligrammini üks kord nädalas.
English: After four weeks, this dose should be increased to 0.5 mg.
Estonian: 4 nädala pärast peab annust suurendama kuni 0,5 milligrammini.
English: What is Ozempic and what is it used for?
Estonian: Mis on Ozempic ja milleks seda kasutatakse?
English: Worsening of diabetic retinopathy has also been observed and will be further investigated.
Estonian: Täheldati diabeetilise retinopaatia süvenemist, mida uuritakse edasi.
English: This is a summary of the European public assessment report (EPAR) for Ozempic.
Estonian: See on ravimi Ozempic Euroopa avaliku hindamisaruande kokkuvõte.
English: The European Medicines Agency concluded that the benefits of Ozempic seen in studies outweighed its risk and recommended it be approved for use in the EU.
Estonian: Euroopa Ravimiamet järeldas, et uuringutes täheldatud Ozempici kasulikkus ületab sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: Why is Ozempic approved?
Estonian: Miks Ozempic heaks kiideti?
English: The starting dose of Ozempic is 0.25 mg once a week.
Estonian: Algannus on 0,25 mg Ozempici üks kord nädalas.
English: This helps with the control of blood glucose levels.
Estonian: See aitab reguleerida vere glükoosisisaldust.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ozempic have been included in the summary of product characteristics and the package leaflet.
Estonian: Ozempici ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Five studies in over 4,000 patients showed that Ozempic lowered levels of HbA1c (a measure of blood glucose) by between 1.2 and 1.8 percentage points over 10 to 13 months.
Estonian: Viies uuringus, milles osales üle 4000 patsiendi, tõendati, et Ozempic vähendas HbA1c (vere glükoosisisalduse näitaja) väärtust 10 kuni 13 kuu jooksul 1,2-1,8%võrra.
English: Serious worsening of diabetic retinopathy (damage to the retina, the light sensitive membrane at the back of the eye) is common (it may affect up to 1 in 10 people).
Estonian: Diabeetilise retinopaatia (silma tagaosas paikneva valgustundliku membraani ehk võrkkesta kahjustus) oluline halvenemine on sage (võib esineda kuni 1 patsiendil 10st).
English: The most common side effects with Ozempic (which may affect more than 1 in 10 people) include problems with the digestive system, such as diarrhoea, vomiting and nausea (feeling sick).
Estonian: Ozempici kõige sagedamate kõrvalnähtude (võivad esineda enam kui 1 patsiendil 10st) hulka kuuluvad seedeprobleemid, nagu kõhulahtisus, oksendamine ja iiveldus.
English: A further study in over 3,000 diabetes patients at high risk of heart problems showed that overall, heart attack, stroke or death occurred less frequently in patients treated with Ozempic (6.6%) than with placebo (8.9%).
Estonian: Veel ühest uuringust, milles osales üle 3000 südameprobleemide suure riskiga diabeedipatsiendi, selgus, et kokkuvõttes oli Ozempiciga ravitud patsientidel südamelihase infarkti, insuldi või surma esinemissagedus väiksem (6,6%) võrreldes platseebot kasutanud patsientidega (8,9%).
English: It is not intended to provide practical advice on how to use Ozempic.
Estonian: Hindamisaruandes ei anta Ozempici kasutamise praktilisi nõuandeid.
English: Ozempic is a diabetes medicine used with diet and exercise to treat adults whose type 2 diabetes is not satisfactorily controlled.
Estonian: Ozempic on diabeediravim ning seda kasutatakse koos dieedi ja füüsilise treeninguga II tüüpi diabeediga (suhkurtõvega) täiskasvanutel, kelle haigus ei ole rahuldavalt reguleeritud.
English: When looking at the three ‘events' separately, fewer patients taking Ozempic had a heart attack or stroke, but rates of death from heart problems were similar in the two groups.
Estonian: Kolme sündmuse eraldi analüüs näitab, et Ozempici kasutanud patsientidel esines harvem südameinfarkti või insulti, kuid südameprobleemidest tingitud surmade hulk oli kahes rühmas sarnane.
English: Ozempic contains the active substance semaglutide.
Estonian: Ozempic sisaldab toimeainena semaglutiidi.
English: In addition, the results indicated that treatment with Ozempic was associated with a beneficial fall in body weight.
Estonian: Lisaks näitasid tulemused, et Ozepmici raviga kaasneb kehakaalu kasulik langus.
English: Other information about Ozempic
Estonian: Muu teave Ozempici kohta
English: Ozempic in these studies compared favourably with other treatments, sitagliptin, exenatide and insulin glargine (which led to reductions of 0.55, 0.92, 0.83 percentage points respectively) and placebo (reductions of up to 0.09 percentage points).
Estonian: Nendes uuringutes võrreldi Ozempici teiste ravimeetoditega, nagu sitagliptiin, eksenatiid, insuliinglargiin ja platseebo, ning saadi soodsad tulemused (glükohemoglobiini sisaldus vähenes vastavalt 0,55, 0,92, 0,83 ja 0,09% võrra).
English: What are the risks associated with Ozempic?
Estonian: Mis riskid Ozempiciga kaasnevad?
English: For more information about treatment with Ozempic, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Ozempiciga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: For practical information about using Ozempic, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Ozempici kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: The active substance in Ozempic, semaglutide, is a ‘GLP-1 receptor agonist'.
Estonian: Ozempici toimeaine semaglutiid on GLP-1 retseptori agonist.
English: How does Ozempic work?
Estonian: Kuidas Ozempic toimib?
English: Treatment with Ozempic also led to weight loss, which is considered beneficial in patients with diabetes.
Estonian: Ravi Ozempiciga põhjustab ka kaalulangust, mida peetakse diabeedipatsientidel kasulikuks.
English: For the full list of all side effects and restrictions with Ozempic, see the package leaflet.
Estonian: Ozempici kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: Ozempic was also shown to be effective at reducing the occurrence of serious health complications associated with diabetes such as heart attack and stroke.
Estonian: Samuti on tõendatud, et Ozempic vähendab diabeediga seotud raskete tüsistuste, nagu südamelihase infarkti ja insuldi esinemissagedust.
English: It is injected under the skin of the belly, the thigh or the upper arm.
Estonian: Subkutaanne süst tehakse kõhu-, reie- või õlavarrepiirkonda.
English: What benefits of Ozempic have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Ozempici kasulikkus?
English: Studies showed that Ozempic is effective at lowering blood glucose levels and reducing the risk of health complications in patients with type 2 diabetes.
Estonian: Uuringutest selgus, et Ozempic on II tüüpi diabeediga patsientidel efektiivne vere glükoosisisalduse ja samuti tüsistuste riski vähendamisel.
English: Ozempic was shown to be effective at controlling blood glucose levels.
Estonian: On tõendatud, et Ozempic reguleerib efektiivselt vere glükoosisisaldust.
English: Ozempic is available as a solution for injection in prefilled pens and can only be obtained with a prescription.
Estonian: Ozempici turustatakse süstelahusena eeltäidetud pensüstaldes ja see on retseptivaktsiin.
English: Ozempic can be used on its own in patients who cannot take metformin (another diabetes medicine).
Estonian: Patsientidel, kes ei saa võtta metformiini (samuti diabeediravim), tohib Ozempicet kasutada ainuravimina.
English: Side effects affecting the digestive system are considered to be manageable.
Estonian: Seedeelundkonnaga seotud kõrvalnähte peeti ohjatavateks.
English: How is Ozempic used?
Estonian: Kuidas Ozempici kasutatakse?
English: 720 ELISA Units
Estonian: 720 ELISA ühikut
English: 1 dose (1 ml) contains: Hepatitis A virus (inactivated)1,2
Estonian: 1 annus (0.5 ml): Hepatiit A viirus (inaktiveeritud)
English: MA (EU) number
Estonian: Müügiloa nr (Euroopa Liidus)
English: 1 pre-filled syringe +
Estonian: 1 eeltäidetud süstal + 1 nõel
English: 1 pre-filled syringe without needle
Estonian: 1 eeltäidetud süstal ilma nõelata
English: What measures are being taken to ensure the safe and effective use of Glustin?
Estonian: Mis meetmed võetakse, et tagada Glustini ohutu ja efektiivne kasutamine?
English: The full EPAR for Glustin can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Glustini kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: Further studies also looked at long-term use of Glustin.
Estonian: Täiendavates uuringutes vaadeldi ka Glustini pikaajalist kasutamist.
English: The European Commission granted a marketing authorisation valid throughout the European Union, for Glustin on 11 October 2000.
Estonian: Euroopa Komisjon andis Glustini müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 11. oktoobril
English: Glustin pioglitazone
Estonian: Glustin pioglitasoon
English: Treatment with Glustin should be reviewed after three to six months, and discontinued in patients who are not deriving sufficient benefit.
Estonian: Glustini ravivastus tuleb 3-6 kuu möödudes läbi vaadata ning lõpetada ravi patsientidel, kellele ravi ei ole piisavalt kasulik.
English: It must also not be used in patients who have or have had bladder cancer or those with blood in the urine that has not yet been investigated.
Estonian: Seda ravimit ei tohi kasutada ka patsiendid, kellel on või on olnud põievähk või kelle uriinis esineb verd, mille põhjust ei ole veel uuritud.
English: Almost 7,000 patients received Glustin in all of the studies combined.
Estonian: Kõigis uuringutes kokku kasutas Glustinit ligikaudu 7000 patsienti.
English: The company that markets Glustin will produce educational material for doctors prescribing the medicine, which will cover the possible risk of heart failure and bladder cancer with treatments that contain pioglitazone, the criteria for selecting patients and the need to review treatment regularly and stop treatment if patients are no longer benefiting.
Estonian: Glustinit turustav ettevõte koostab ravimit määravatele arstidele teabematerjalid, milles selgitatakse südamepuudulikkuse ja kusepõie vähi võimalikku riski pioglitasooni sisaldavate ravimite kasutamisel, patsientide valikukriteeriume ning vajadust ravi regulaarselt läbi vaadata ja lõpetada, kui see ei ole patsientidele enam kasulik.
English: The most common side effects with Glustin (seen in between 1 and 10 patients in 100) are upper respiratory tract infection (colds), hypoaesthesia (reduced sense of touch), visual disturbance, bone fractures and increased weight.
Estonian: Glustini kõige sagedamad kõrvalnähud (esinenud 1-10 patsiendil 100st) on ülemiste hingamisteede nakkused (nohu), hüpesteesia (vähenenud puutetundlikkus), nägemishäired, luumurrud ja kehakaalu suurenemine.
English: The CHMP decided that Glustin's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Glustini kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: The recommended starting dose of Glustin is 15 or 30 mg once a day.
Estonian: Glustini soovitatav algannus on 15 või 30 mg üks kord ööpäevas.
English: Other information about Glustin:
Estonian: Muu teave Glustini kohta
English: This is a summary of the European public assessment report (EPAR) for Glustin.
Estonian: See on ravimi Glustin Euroopa avaliku hindamisaruande kokkuvõte.
English: If Glustin is used in combination with other diabetes medicines, other side effects may occur.
Estonian: Glustini kasutamisel koos teiste diabeediravimitega võivad esineda ka muud kõrvalnähud.
English: The active substance in Glustin, pioglitazone, makes cells (fat, muscle and liver) more sensitive to insulin, which means that the body makes better use of the insulin it produces.
Estonian: Glustini toimeaine pioglitasoon suurendab rakkude (rasva-, lihase- ja maksarakud) tundlikkust insuliini suhtes, mis tähendab, et organism kasutab enda toodetavat insuliini paremini ära.
English: Glustin is a medicine that contains the active substance pioglitazone.
Estonian: Glustin on ravim, mis sisaldab toimeainena pioglitasooni.
English: What is Glustin?
Estonian: Mis on Glustin?
English: For more information about treatment with Glustin, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Glustiniga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Glustin.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Why has Glustin been approved?
Estonian: Miks Glustin heaks kiideti?
English: • together with insulin in patients who are not satisfactorily controlled with insulin alone and cannot take metformin.
Estonian: • koos insuliiniga patsientidel, kelle haigust üksnes insuliin rahuldavalt ei reguleeri ja kes ei saa kasutada metformiini.
English: The studies measured the level of a substance in the blood called glycosylated haemoglobin (HbA1c), which gives an indication of how well the blood glucose is controlled.
Estonian: Uuringutes mõõdeti glükohemoglobiini (HbA1c) sisaldust veres, mis näitab, kui hästi organism vere glükoosisisaldust reguleerib.
English: The doses of Glustin may need to be adjusted when given with some other medicines such as gemfibrozil (used to lower cholesterol) or rifampicin (an antibiotic used to treat tuberculosis).
Estonian: Glustini annuseid võib olla vaja korrigeerida, kui ravimit kasutatakse koos teatud teiste ravimitega (näiteks kolesteroolisisaldust vähendava ravimi gemfibrosiili või tuberkuloosiravimi antibiootikumi rifampitsiiniga).
English: What is the risk associated with Glustin?
Estonian: Mis riskid Glustiniga kaasnevad?
English: Glustin is used to treat type 2 diabetes in adults (aged 18 years or over), particularly those who are overweight.
Estonian: Glustinit kasutatakse eelkõige ülekaaluliste täiskasvanud (vähemalt 18-aastaste) patsientide II tüüpi diabeedi (suhkurtõve) raviks.
English: For the full list of all side effects reported with Glustin, see the package leaflet.
Estonian: Glustini kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Some studies also looked at combining Glustin with a sulphonylurea, insulin or metformin, or with the combination of metformin and a sulphonylurea.
Estonian: Mõnes uuringus vaadeldi ka Glustini kasutamist koos sulfonüüluurearavimi, insuliini või metformiiniga või metformiini ja sulfonüüluurearavimi kombinatsiooniga.
English: It is used in addition to diet and exercise as follows:
Estonian: Seda kasutatakse koos dieedi ja füüsilise koormusega
English: Glustin must not be used in patients who have problems with their liver, patients who have had heart failure (when the heart does not work as well as it should) or patients with diabetic ketoacidosis (a complication of diabetes).
Estonian: Glustinit ei tohi kasutada patsiendid, kellel on maksaprobleeme, südamepuudulikkus või diabeetiline ketoatsidoos (diabeedi teatud tüsistus).
English: Glustin also improved the glucose control obtained in type 2 diabetes when it was added to existing treatment with a sulphonylurea, insulin or metformin, or the combination of metformin and a sulphonylurea.
Estonian: Glustin parandas II tüüpi diabeediga patsientide vere glükoosisisalduse reguleeritavust ka juhul, kui Glustin lisati senisele ravile sulfonüüluurearavimi, insuliini või metformiiniga või metformiini ja sulfonüüluurearavimi kombinatsiooniga.
English: Glustin led to a decrease in the level of HbA1c, indicating that blood glucose levels had been reduced at doses of 15, 30 and 45 mg. Glustin on its own was shown to be as effective as metformin and gliclazide.
Estonian: Glustin vähendas HbA1c-sisaldust, mis tõendas, et annuste 15 mg, 30 mg ja 45 mg korral vere glükoosisisaldus vähenes.